Featured news from NHIVNA
HIV-related news from NAM
The Pros and Cons of PrEP: trial volunteers recount their experience of the ADAPT study
Gus Cairns, 2015-07-22 05:40:00
The reasons whether or not people come forward for pre-exposure prophylaxis (PrEP) or take it once prescribed are likely to be very mixed, and dependent as much on local political and cultural beliefs as they are on more personal factors like relationship status, the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) heard yesterday.
The HPTN067 (ADAPT) study is a phase II open-label study of Truvada PrEP based in three world cities (Cape Town, Bangkok and Harlem, New York). It aims to evaluate the ease of use and feasibility of three different PrEP regimens: daily dosing, timed dosing (meaning two doses a week plus an extra dose two hours after sex if it happens), and event-driven dosing, which means one dose 2-24 hours ahead of anticipated sex and one two hours after if it happens.
For the data on adherence, pill usage and HIV infections, see Roger Pebody’s report here.
Each of the three city studies also had qualitative studies attached to it so that participants could relate their experience of taking PrEP.
Source:1
